From reddit:

Go to Livimmune
r/Livimmune
•
5 hr. ago
BuildGoodThings

Keeping up in 2024 with the research.
Cytodyn is getting busy and they are backing up each of these indications with presentations, papers, studies, and trials since March 2024 for a reason IMO. They are gathering and presenting all this data to show the depth of what the molecule can do so that large pharma realizes that they will need to make serious offers to this company which is now run by a team of knowledgeable and effective people. Here below are just some of the things happening. This list doesn't include everything.

Cancer Program

Cancer: CRC (colorectal)

awaiting phase 2 trial protocol approval and screening

(n.b. previous unpublished preclinical study)

Cancer: Glioblastoma (brain)

awaiting pre-clinical study results

Cancer: TNBC (breast)

awaiting 2 clinical trials papers

awaiting start of additional preclinical study

(n.b. 3 previous clinical trials completed)

HIV Program

Lines of research include

leronlimab as monotherapy

ART + leronlimab

PeP combo with ART + bNAbs (PGT121-LS & VRC07-523-LS) + Leronlimab (also potential cure)

Cure- Gene therapy, AAV viral vector

Cure- Stem cell (includes announced LATCH trial)

PrEP Mothers to newborns (leronlimab PLS)

4 preclinical presentations (oral and poster) made in 2024

1 preclinical paper published in 2024

awaiting a clinical trial paper

awaiting start of 2 clinical trials (LATCH)

(n.b. numerous previous clinical trials completed)

Inflammation Program

Alzheimer's

awaiting start of clinical trial

Chronic Fatigue Syndrome

awaiting start of clinical trial

Covid-19: Mild-Moderate

published phase 2 paper in 2024

awaiting start of clinical trial

(n.b. previous clinical trial completed)

Covid-19: Severe & Critical

awaiting clinical trial paper

(n.b. previous clinical trial completed)

Covid-19: PASC (longhaulers)

published phase 2 letter to editor in 2024

(n.b. previous clinical trial completed)

Inflammation (Chronic in HIV patients)

awaiting phase 2 trial patient screening to begin

MASH (liver)

preclinical study results released by press release in 2024

awaiting additional preclinical study

awaiting a clinical trial paper

(n.b. previous clinical trial completed)

Long Acting Leronlimab Program

Long-acting Leronlimab (in HIV)

1 preclinical presentation made in 2024